Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT05098210

Anatomic Stage IV Breast Cancer AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Locally Advanced Cutaneous Melanoma +22 more

RECRUITING PHASE1

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

NCT05389514

KRAS G12V Mutant Advanced Epithelial Cancers

TEMPORARILY_NOT_AVAILABLE

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

NCT03059823

Locally Advanced Solid Tumors Metastatic Solid Tumors

COMPLETED PHASE1

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

NCT03387085

Triple Negative Breast Cancer

TERMINATED PHASE1/PHASE2

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

NCT00037037

Melanoma (Skin)

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma Squamous Cell Carcinoma Hodgkin Lymphoma Non-hodgkin Lymphoma Breast Cancer Prostate Cancer Gastric Cancer Ovarian Cancer Acute Leukemia Pancreatic Cancer Spindle Cell Sarcoma Cancer Tumor, Solid Tumor, Brain Esophageal Andeocarcinoma Mixed Phenotype AML Desmoplastic Round Cell Sarcoma